Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence.

Publication ,  Journal Article
Gu, C; Li, Q; Zhu, Y; Qu, Y; Zhang, G; Wang, M; Yang, Y; Wang, J; Jin, L; Wei, Q; Ye, D
Published in: Prostate Cancer Prostatic Dis
December 2015

BACKGROUND: Telomere-related genes play an important role in carcinogenesis and progression of prostate cancer (PCa). It is not fully understood whether genetic variations in telomere-related genes are associated with development and progression in PCa patients. METHODS: Six potentially functional single-nucleotide polymorphisms (SNPs) of three key telomere-related genes were evaluated in 1015 PCa cases and 1052 cancer-free controls, to test their associations with risk of PCa. Among 426 PCa patients who underwent radical prostatectomy (RP), the prognostic significance of the studied SNPs on biochemical recurrence (BCR) was also assessed using the Kaplan-Meier analysis and Cox proportional hazards regression model. The relative telomere lengths (RTLs) were measured in peripheral blood leukocytes using real-time PCR in the RP patients. RESULTS: TEP1 rs1760904 AG/AA genotypes were significantly associated with a decreased risk of PCa (odds ratio (OR): 0.77, 95% confidence interval (CI): 0.64-0.93, P=0.005) compared with the GG genotype. By using median RTL as a cutoff level, RP patients with TEP1 rs1760904 AG/AA genotypes tended to have a longer RTL than those with the GG genotype (OR: 1.55, 95% CI: 1.04-2.30, P=0.031). A significant interaction between TEP1 rs1713418 and age in modifying PCa risk was observed (P=0.005). After adjustment for clinicopathologic risk factors, the presence of heterozygotes or rare homozygotes of TEP1 rs1760904 and TNKS2 rs1539042 were associated with BCR in the RP cohorts (hazard ratio: 0.53, 95% CI: 0.36-0.79, P=0.002 and hazard ratio: 1.67, 95% CI: 1.07-2.48, P=0.017, respectively). CONCLUSIONS: These data suggest that genetic variations in the TEP1 gene may be biomarkers for risk of PCa and BCR after RP.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Prostate Cancer Prostatic Dis

DOI

EISSN

1476-5608

Publication Date

December 2015

Volume

18

Issue

4

Start / End Page

310 / 316

Location

England

Related Subject Headings

  • Urology & Nephrology
  • Telomere
  • Tankyrases
  • Risk Factors
  • Risk
  • RNA-Binding Proteins
  • Prostatic Neoplasms
  • Prognosis
  • Polymorphism, Single Nucleotide
  • Neoplasm Staging
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gu, C., Li, Q., Zhu, Y., Qu, Y., Zhang, G., Wang, M., … Ye, D. (2015). Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence. Prostate Cancer Prostatic Dis, 18(4), 310–316. https://doi.org/10.1038/pcan.2015.27
Gu, C., Q. Li, Y. Zhu, Y. Qu, G. Zhang, M. Wang, Y. Yang, et al. “Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence.Prostate Cancer Prostatic Dis 18, no. 4 (December 2015): 310–16. https://doi.org/10.1038/pcan.2015.27.
Gu C, Li Q, Zhu Y, Qu Y, Zhang G, Wang M, et al. Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence. Prostate Cancer Prostatic Dis. 2015 Dec;18(4):310–6.
Gu, C., et al. “Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence.Prostate Cancer Prostatic Dis, vol. 18, no. 4, Dec. 2015, pp. 310–16. Pubmed, doi:10.1038/pcan.2015.27.
Gu C, Li Q, Zhu Y, Qu Y, Zhang G, Wang M, Yang Y, Wang J, Jin L, Wei Q, Ye D. Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence. Prostate Cancer Prostatic Dis. 2015 Dec;18(4):310–316.

Published In

Prostate Cancer Prostatic Dis

DOI

EISSN

1476-5608

Publication Date

December 2015

Volume

18

Issue

4

Start / End Page

310 / 316

Location

England

Related Subject Headings

  • Urology & Nephrology
  • Telomere
  • Tankyrases
  • Risk Factors
  • Risk
  • RNA-Binding Proteins
  • Prostatic Neoplasms
  • Prognosis
  • Polymorphism, Single Nucleotide
  • Neoplasm Staging